Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma

References

• Horning S A, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Ezdinli E Z, Anderson J R, Melvin F, Glick J H, Davis T E, O'Connell M J. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 1985; 3: 769–775
   PubMed Web of Science ®Google Scholar
• Lukes R J, Collins R D. Immunologic characterzation of human malignant lymphomas. Cancer 1974; 34: 1488–1503
   PubMed Web of Science ®Google Scholar
• National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage: the non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G M, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908
   PubMed Web of Science ®Google Scholar
• Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998; 89: 748–756
   PubMedGoogle Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes aB cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–186
   PubMed Web of Science ®Google Scholar
• Michon J M, Gey A, Moutel S, Tartour E, Meresse V, Fridman W, et al. In vivo induction of functional FcRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). Br J Haematol 1998; 100: 550–556
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. IARC Press, Lyon 2001
   Google Scholar
• Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The clinical trial review committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250–257
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma International Prognostic Index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, Tamaru J, et al. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clin Cancer Res 2004; 10: 4077–4082
   PubMed Web of Science ®Google Scholar
• Berinstein N L, Grillo-Lopez A J, White C A, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995–1001
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-Lopez A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Davis T A, White C A, Grillo-Lopez A J, Velasquez W S, Link B, Maloney D G, et al. Sigle-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851–1857
   PubMed Web of Science ®Google Scholar
• Longo D, DeVita V, Jaffe E, Mauch P, Urba W J. Lymphocytic lymphomas. Cancer: Principles & Practice of Oncology, 4th edn, V T DeVita, Jr, S Hellman, S Rosenberg. Lippincott, Philadelphia, PA 1993; 1859–1927
   Google Scholar
• Levine E G, Arthur D C, Frizzera G, Peterson B A, Hurd D D, Bloomfield C D, et al. Cytogenetic abnormalities predict clinical outcome in non-Hodgkin's lymphoma. Ann Intern Med 1988; 108: 14–20
   PubMed Web of Science ®Google Scholar
• Pezzella F, Jones M, Ralfkiaer E, Ersboll J, Gatter K C, Mason D Y. Evaluation of bcl-2 protein expression and 14:18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 1992; 65: 87–89
   PubMed Web of Science ®Google Scholar
• Gribben J G, Freedman A S, Woo S D, Blake K, Shu R S, Freeman G, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 23: 4711–4716
   Web of Science ®Google Scholar